Navigation Links
Antibody in Biological Technology

Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody

... Inc., a clinical-stage company developing novel antibody therapeutics that target cancer stem cells, today ... and recurrence." OMP-21M18 is a monoclonal antibody that blocks DLL4 signaling to reduce tumor growth ... About OMP-21M18 OMP-21M18 is a monoclonal antibody optimized to block a key signaling pathway in ...

Micromet Closes $80.5 Million Public Offering of Common Stock

... antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal ... are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical ... in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is ...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

... the European Medicines Agency (EMEA) for BiTE antibody blinatumomab (MT103) for acute lymphoblastic leukemia (ALL). Blinatumomab is a novel therapeutic antibody that activates a patient's T cells to seek out ... antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal ...

Micromet Announces Pricing of Public Offering of Common Stock

... antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal ... are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical ... in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is ...

Micromet Announces Public Offering of Common Stock

... antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal ... are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical ... in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is ...

PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009

... PDL is focused on maximizing the value of its antibody humanization patents and related assets. The ... royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late ...

Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009

... antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal ... are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical ... in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is ...

OMT announces a breakthrough in the development of a novel human antibody platform

... the development of OMT's novel human monoclonal antibody platform. "Creating a knockout rat was the ... of the paper. "Inactivation of endogenous rat antibody expression is essential for human antibody expression in genetically engineered animals. To ...

Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech

... they have entered into a licensing agreement for antibody therapeutic rights under Peregrine's preclinical anti-VEGF (Vascular Endothelial Growth Factor) antibody program. Under the terms of the agreement, ... property portfolio, including the fully human antibody r84, which was discovered by Affitech and jointly ...

Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies

... all of which have successfully induced antibody responses in mice. Novavax scientists have now ... a broad set of immune responses including antibody and cell mediated immune responses to prevent ... that the RSV-F vaccine induced neutralizing antibody responses at all doses evaluated. The highest ...

Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies

... approach to targeting tumor-associated proteins. antibody targeting of tumor-associated proteins has ... as we continue to grow our therapeutic antibody portfolio." "CII has developed several ... for cancer." Morphotek will apply its antibody discovery technologies, including its proprietary ...

BioWa Announces License of POTELLIGENT(R) Technology to Merck KGaA

... development and commercialization of their antibody therapies with enhanced antibody-dependent ... Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. POTELLIGENT((R)) Technology ...

MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus

... MGAWN1 MGAWN1 is a humanized monoclonal antibody that specifically recognizes the envelope (E) ... set of capabilities in monoclonal antibody product development. The company's product ... lead program, teplizumab, is an anti-CD3 antibody being developed for the treatment of autoimmune ...

Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease

... "Morphotek is an industry leader in antibody discovery and development," said Sanj K. Patel, ... collaboration." "We have a rich pipeline of antibody products such as MORAb-003, or farletuzumab, for ... may enhance the manufacturing process for our antibody products as a means to fulfill Eisai's hhc ...

Micromet Added to Russell 3000 Index

... antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal ... are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical ... in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is ...

Paulo F. Costa Joins MacroGenics Board of Directors

... that MacroGenics has one of the best monoclonal antibody therapeutics programs, including a rich pipeline ... set of capabilities in monoclonal antibody product development. The company's product ... lead program, teplizumab, is an anti-CD3 antibody being developed for the treatment of autoimmune ...

Sigma-Aldrich and Atlas Antibodies Announce 2,300 New, Highly Validated Prestige Antibodies(RM)

... SIAL ) today announced the release of over 2,300 antibody additions to its Prestige Antibodies(R) powered ... Proteome Resource's goal to develop at least one antibody to all 22,000 non-redundant human proteins by ... Sigma-Aldrich has significantly expanded our antibody offerings, the latest step in our long-term plan ...

New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease

... dose of Prevenar 13 or Prevenar at 12 months. antibody response was measured at month 13. Both of the ... and 11 months of age. Assessment of functional antibody levels (serotype specific opsonphagocytic assay) ... were either comparable to or greater than the IgG antibody concentrations achieved in infants after a 3-dose ...

PDL BioPharma Provides Second Quarter 2009 Revenue Guidance of Approximately $125 Million

... PDL is focused on maximizing the value of its antibody humanization patents and related assets. The ... royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late ...

Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009

... antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal ... are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical ... in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is ...

Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting

... II trial of its lead anti-phosphatidylserine antibody bavituximab in combination with docetaxel in ... 7.4 months. Bavituximab is a monoclonal antibody with a unique anti-cancer mechanism that works by ... treatments. Bavituximab is a monoclonal antibody that binds specifically to these phospholipids ...

NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS

... results reported for cetuximab, an EGFR-targeting antibody marketed as Erbitux(R), but that this efficacy ... assess the safety and efficacy of h-R3 monoclonal antibody against EGFR in combination with chemoradiation ... Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple ...

Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel

... clinical trial investigating its anti-EpCAM human antibody adecatumumab (MT201) in combination with the ... n=19 evaluable for efficacy). Adecatumumab is an antibody that targets EpCAM, a tumor antigen known to be ... Her-2 and thus do not qualify for Her-2-targeting antibody therapy." (1) Sebastian, M. et al. (2009). ...

Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO

... treated with anti-CD19/-CD3 bispecific BiTE(R) antibody blinatumomab. 14th Congress of EHA (2009), ... and antitumor activity of 3-weekly anti-EpCAM antibody adecatumumab (MT201) in combination with ... and autoimmune diseases. The Company's novel antibody technology is based on its proprietary ...

Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement

... a subset of antibodies in Morphotek's therapeutic antibody pipeline. The agreement will reserve capacity for ... scale expression and purification of commercial antibody products. They have demonstrated their ability to ... production, quality goals and timelines for our antibody programs." "Lonza is excited to participate ...

PDL BioPharma Announces First Quarter 2009 Financial Results

... PDL is focused on maximizing the value of our antibody humanization patents and related assets. PDL receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late ...

Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009

... and autoimmune diseases. The Company's novel antibody technology is based on its proprietary BiTE(R) antibody platform, representing a new class of antibodies ... development. The Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase ...

Medarex Announces 2009 First Quarter Financial Results

... MEDI-546, a fully human anti-type 1 interferon antibody for the treatment of scleroderma, a chronic ... inflammatory diseases and is the second human antibody generated using Medarex's UltiMAb(R) technology ... & Co, Inc., for the MDX-066 and MDX-1388 antibody combination treatment for C. difficile ...

Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments

... by HGS, generating and developing all monoclonal antibody candidates using proprietary Morphotek ... in the development and commercialization of each antibody candidate. CONFERENCE CALL HGS ... treatment of cancer, led by the TRAIL receptor antibody HGS-ETR1 and a small-molecule antagonist of IAP ...

Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology

... and prostate cancer, as well as for an anti-PD-1 antibody for cancer treatment, have been selected to be ... "Phase 2 trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly known as MDX-010) with a ... commercialize a broad range of fully human antibody product candidates for itself and its partners. ...

PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research

... to respond to natural infection by producing antibody due to immunologic memory.) The three dose ... SparVax(TM) was safe, well-tolerated and produced antibody responses comparable to the currently licensed ... Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax ...

Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110

... in Denver, Colorado, showing that its BiTE(R) antibody MT110 can eliminate cancer stem cells (1). Cancer ... The data presented at AACR show that the BiTE antibody MT110 can direct T cells to eliminate ... a study of MT110 in mice showed that the BiTE antibody eliminated even large numbers of implanted cancer ...

AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies

... of the modified anti-CD20 human-mouse chimeric antibody exposed unexpected adverse activity that may not ... increase the binding strength between the antibody and the target antigen, as determined repeatedly ... and " Oxidative Modification Of An Anti-CD20 antibody Imparts Autophilic Binding Kinetics ", (AACR# ...

Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR

... 1 and 2; AMG 479, a fully human monoclonal antibody antagonist of the type 1 insulin-like growth ... (IGF-1R) and AMG 102, a fully human monoclonal antibody antagonist of HGF, the ligand for the c-Met ... Overview: Evaluated the effect of a novel antibody to the IGF-1R (AMG 479) on cell ...

Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth

... the potent anti-tumor activity of a BiTE antibody binding to carcinoembryonic antigen (CEA) and to ... as target antigen for development of a new BiTE antibody program because CEA is widely expressed on the ... on the surface of cancer cells, thereby limiting antibody efficacy. The new study shows that novel BiTE ...

BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis

... development and commercialization of their antibody therapies with enhanced antibody-dependent ... Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. POTELLIGENT(R) Technology involves ...

Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009

... and autoimmune diseases. The Company's novel antibody technology is based on its proprietary BiTE(R) antibody platform, representing a new class of antibodies ... development. The Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase ...

Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology

... by HGS, generating and developing all monoclonal antibody candidates using proprietary Morphotek ... proof of concept studies. With respect to each antibody candidate, HGS and Morphotek will have the right ... with Human Genome Sciences to apply our antibody technology to a range of novel targets that stem ...

Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics

... of Sir Walter Bodmer and Bernard Fox to its BiTE antibody advisory panel. Other members of the company's ... and autoimmune diseases. The Company's novel antibody technology is based on its proprietary BiTE(R) antibody platform, representing a new class of antibodies ...

Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research

... "Efficacy of MDX-1110, an anti-Fucosyl-GM1 antibody in a SCLC tumor model" (Abstract #838), B. Chen - ... "Efficacy and Toxicity of anti-mesothelin antibody drug conjugate" (Abstract #3235), C. Rao - Poster ... commercialize a broad range of fully human antibody product candidates for itself and its partners. ...
Other Contents
(Date:9/16/2014)... , Sept. 16, 2014  Cross Match ... management solutions, announced today the launch of its ... authenticate the identity of an individual using their ... Verifier Sentry rapidly reads credential documents with embedded ... by matching the biometric to a live scan ...
(Date:9/15/2014)... 15, 2014) The so-called central dogma of ... long provided a simplified explanation for how genetic ... , In reality, of course, the process ... articulated nearly 60 years ago by Nobel Laureate ... For one, there are multiple types of RNA, ...
(Date:9/15/2014)... research has determined that a single group of microorganisms ... B12 production in the oceans, with implications for the ... B12 is an essential molecule required by most life ... relatively small group of microorganisms because it is so ... key role in maintaining the brain and nervous systems, ...
Breaking Biology News(10 mins):Cross Match Launches New Identity Management Handheld Solution 2Scientists discover RNA modifications in some unexpected places 2Researchers discover new producer of crucial vitamin 2
(Date:9/16/2014)... patients who received hypofractionated (HPFX) radiation therapy (RT) ... as bladder and bowel function were at similar ... presented today at the American Society for Radiation ... that parallel quality of life outcomes occurred between ... HPFX RT. , The phase I/II trial enrolled ...
(Date:9/16/2014)... (PET) tracer is effective in diagnosing concussion-related brain disease ... case study conducted at the Icahn School of Medicine ... in New Haven, and published September 16 in the ... results suggest that an experimental radiolabeled compound called [18 ... called tau that accumulates in the brain with repetitive ...
(Date:9/16/2014)... any other workplace incident, a statistic that transport safety ... being hosted by QUT,s Centre for Accident Research & ... in Transport Conference (OSIT) to be held on the ... experts from all facets of transport safety including roads, ... safety. , CARRS-Q research fellow Darren Wishart said the ...
(Date:9/16/2014)... soon better predict a man,s risk of getting prostate ... the largest-ever analysis of the cancer,s genetic biomarkers, reported ... of Health and Biomedical Innovation,s Dr Jyotsna Batra and ... in the large consortia of research hubs around the ... genetic markers in 80,000 men. , "It,s the largest ...
(Date:9/16/2014)... September 16, 2014 Non-small cell lung cancer (NSCLC) ... smokers at the time of diagnosis have a ... (SPLC) compared to those who are current smokers, ... a higher risk of SPLC, according to research ... Oncology,s (ASTRO,s) 56th Annual Meeting. , The analysis ...
Breaking Medicine News(10 mins):Health News:Prostate cancer patients who receive hypofractionated RT report consistent QoL 2Health News:Prostate cancer patients who receive hypofractionated RT report consistent QoL 3Health News:Neuroimaging technique identifies concussion-related brain disease in living brain 2Health News:Neuroimaging technique identifies concussion-related brain disease in living brain 3Health News:CARRS-Q Host International Transport Safety Conference 2Health News:New gene research helps pinpoint prostate cancer risk 2Health News:NSCLC patients who never smoked or who quit smoking have lower risk of developing secondary cancers 2Health News:NSCLC patients who never smoked or who quit smoking have lower risk of developing secondary cancers 3
Other TagsOther Tags